ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "immunology"

  • Abstract Number: 0185 • ACR Convergence 2021

    Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects

    Silke Roedder1, Emily Wendt2, Chad Burris2, Jonathan Nazareon2, Grace Park3, Phil Pangilinan2, Gianna Huang2, Anubhav Mathur2, James Taylor2, Andrew Billin2 and Franziska Matzkies4, 1Gilead Sciences, Menlo Park, CA, 2Gilead Sciences, Foster City, CA, 3Gilead Sciences, Seattle, WA, 4Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of autoimmune diseases including Rheumatoid Arthritis (RA) and Lupus Erythematosus (LE). Immune complexes…
  • Abstract Number: 1013 • ACR Convergence 2021

    SARS-CoV-2 Antibody Phenotype and Immune Gene Expression in Multi-system Inflammatory Syndrome in Children

    Kate Webb1, Thandeka Moyo-Gwete2, Simon Mendelsohn3, Claire Butters4, Simone Richardson5, Heidi Facey-Thomas4, Debbie Abrahams4, Mashudu Madzivhandila5, Zanele Makhado5, Frances Ayres5, William Horsnell6, Neilia Manamela5, Richard Baguma3, Stanley Kimbung Mbandi3, Mzwandile Erasmus3, Thomas Scriba3, Liesl Zühlke7, Penny Moore5, George Kassiotis8 and Christiaan Scott4, 1Paediatric Rheumatology University of Cape Town/ Francis Crick Institute, Cape Town, South Africa, 2National Institute of Communicable Diseases/University of Witwatersrand, Johannesburg, South Africa, 3South African TB vaccine initiative, IIDM, University of Cape Town, Cape Town, South Africa, 4Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, 5National Institute of Communicable Diseases/University of Witwatersrand, Cape Town, South Africa, 6University of Cape Town, Cape Town, South Africa, 7Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, 8Retroviral Immunology, Francis Crick Institute, London, United Kingdom

    Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a severe disease that affects a small proportion of children exposed to Severe Acute Respiratory Syndrome Coronavirus…
  • Abstract Number: 0262 • ACR Convergence 2021

    High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients

    Clément TRIAILLE1, Cécile BOULANGER2, Tatiana SOKOLOVA1, Laurent MERIC de BELLEFON3, Adrien NZEUSSEU TOUKAP4, Christine GALANT5, Nisha LIMAYE6, Bernard LAUWERYS7 and Patrick DUREZ8, 1Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 2Service d’Hématologie, Oncologie et Rhumatologie pédiatrique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 3Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 4Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium, 5Service d’Anatomie Pathologique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 6Genetics of Autoimmune Diseases and Cancer, de Duve Institute, Université catholique de Louvain, Brussels, Belgium, 7UCB Pharma, Brussels, Belgium, 8Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium

    Background/Purpose: Increasing evidence indicates that synovial tissue analysis can deliver pathophysiological insights but also individual clinically-relevant information in adult-onset inflammatory arthritides. Little is known about…
  • Abstract Number: 1092 • ACR Convergence 2021

    Altered Metabolic Pathways in Synovial Fibroblasts of Individuals at Risk of Developing Rheumatoid Arthritis

    Tineke de Jong1, Simone Denis1, Paul Tak2, Riekelt Houtkooper1 and Lisa van Baarsen1, 1Amsterdam UMC, Amsterdam, Netherlands, 2Candel Therapeutics, Cambridge, United Kingdom

    Background/Purpose: Cellular metabolism has been studied in fibroblast-like synoviocytes (FLS) of rheumatoid arthritis (RA) and osteoarthritis (OA) patients and raises the question whether observed metabolic…
  • Abstract Number: 0437 • ACR Convergence 2021

    Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab

    Victoria Furer1, Tali Eviatar2, Devy Zisman3, Hagit Peleg4, Daphna Paran5, David Levartovsky1, Ilana Kaufman6, Michael Zisapel1, Ofir Elalouf7, Roni Meidan1, Adi Broyde8, Ari Polachek9, Jonathan Wollman7, Katya Meridor10, Hila Nochomovitz1, Adi Silberman1, Dana Rosenberg1, Joy Feld11, Amir Haddad12, Tal Gazitt13, Muna Elias3, Nizar Hijaze14, Fadi Kharouf4, Gabi Shefer1, Orly Sharon1, Sara Pel1, Sharon Nevo1 and Ori Elkayam15, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Givataim, Israel, 3Carmel Medical Center, Haifa, Israel, 4Hadassah Medical Center, Jerusalem, Israel, 5Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, 6Tel Aviv Sourasky Medical Center, Petach Tiqwa, Israel, 7Tel Aviv Medical Center, Herzliya, Israel, 8Tel Aviv Sourasky Medical Center, KIBBUTZ GIVAT HAIM I, Israel, 9Sourasky Medical Center, Petah-Tikva, Israel, 10Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, 11Carmel and Zvulun Medical Centre, Haifa, Israel, 12Carmel Medical Centre, Haifa, Israel, 13Carmel Hospital, Haifa, Israel, 14Carmel medical centre, Tamra, Israel, 15Tel Aviv Medical Center, Tel Aviv, Israel

    Background/Purpose: Rituximab (RTX) has been associated with impaired humoral response to vaccination. This study aim was to identify the predictors for a lack of humoral…
  • Abstract Number: 1224 • ACR Convergence 2021

    Low CD39 Expression on B Cells Predicts the Occurrence of Anti-Drug Antibodies in RA Patients Treated with Rituximab

    Samuel Bitoun1, Bineta Ly2, Signe Hässler3, Audrey Paoletti4, Aude Gleizes5, Salima Hacein-Bey5, Philippe Bröet3, Marc Pallardy6 and Xavier Mariette7, 1Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, 2INSERM U1184, Université Paris Saclay, Le Kremlin Bicêtre, France, 3CESP, INSERM UMR 1018, Universite Paris-Saclay, Villejuif, France, 4INSERM U1184, Université Paris Saclay, le kremlin bicetre, France, 5Hôpital Bicètre, APHP, Université Paris-Saclay, Le Kremlin Bicêtre, France, 6Faculté de Pharmacie, Université Paris-Saclay, Chatenay Mallabry, France, 7Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: Anti-Drug antibodies (ADAb) are well studied and have an impact on response to treatment with monoclonal anti-TNF biologics. Rituximab treatment has an important immunogenic…
  • Abstract Number: 0439 • ACR Convergence 2021

    Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer

    Amy Cunningham-Bussel1, Jiaqi Wang2, Lauren Prisco3, Lily Martin2, Kathleen Vanni2, Alessandra Zaccardelli2, Mazen Nasrallah4, Lydia Gedmintas2, Lindsey MacFarlane5, Nancy Shadick6, Mark M. Awad7, Osama E. Rahma7, Nicole LeBoeuf8, Ellen Gravallese9 and Jeffrey Sparks2, 1Brigham and Women's, Brookline, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Pound Ridge, MA, 4MGH, Somerville, MA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham & Women's Hospital, Boston, MA, 7Dana-Farber Cancer Institute, Boston, 8Brigham and Women's Hospital, Department of Dermatology, Boston, MA, 9Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Immune-related adverse events (irAEs) are a frequent and serious complication of immune checkpoint inhibitor (ICI) treatment for cancer, which can resemble primary rheumatic diseases.…
  • Abstract Number: 1250 • ACR Convergence 2021

    Abatacept and Other DMARDs Have Common Transcriptomic Effects on RA Synovial Tissue

    Clément TRIAILLE1, Tatiana SOKOLOVA1, Gaëlle TILMAN1, Laurent MERIC de BELLEFON2, Christine GALANT3, Patrick DUREZ4, Bernard LAUWERYS5 and Nisha LIMAYE6, 1Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 2Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 3Service d’Anatomie Pathologique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 4Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium, 5UCB Pharma, Brussels, Belgium, 6Genetics of Autoimmune Diseases and Cancer, de Duve Institute, Université catholique de Louvain, Brussels, Belgium

    Background/Purpose: Our goal was to assess histological and transcriptomic effects of Abatacept (ABA) on RA synovium, and to compare them with previously published data obtained…
  • Abstract Number: 0461 • ACR Convergence 2021

    Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria

    Meagan Chriswell1, Jennifer Seifert2, Michelle Bloom3, Cliff Rims4, Marie Feser5, Kevin Deane6, Jill Norris7, Eddie James8, Jane Buckner9, William Robinson10, V. Michael Holers11 and Kristine Kuhn12, 1UC Denver SOM, Denver, CO, 2University of Colorado School of Medicine, Littleton, CO, 3Stanford University, Redwood City, CA, 4Benaroya Research Institute, Seattle, WA, 5University of Colorado Denver, Aurora, CO, 6University of Colorado Denver, Denver, CO, 7Colorado School of Public Health, Aurora, CO, 8Benaroya Research Institute at Virginia Mason, Monroe, WA, 9Benaroya Research Institute at Virginia Mason, Seattle, WA, 10Stanford University, Palo Alto, CA, 11University of Colorado, Denver, CO, 12University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Circulating autoantibodies like ACPA frequently develop years before symptoms of RA, during which the individual is at-risk for disease. Several lines of evidence suggest…
  • Abstract Number: 1484 • ACR Convergence 2021

    B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis

    Fatima Alduraibi1, Huma Fatima1, Winn Chatham2, Hui-Chen Hsu1 and John Mountz1, 1University of Alabama Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Our laboratory previously demonstrated a strong association of B cell intracellular interferon beta (IFNβ) with the development of anti-Smith/ribonuclear protein (Sm/RNP), anti-DNA, and lupus…
  • Abstract Number: 0449 • ACR Convergence 2020

    Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca

    Blake Warner1, Billel Gasmi2, David Kleiner3, Paola Perez Riveros4, Daniel Barber5, Shunsuke Sakai5 and Alan Baer6, 1National Institute of Dental and Craniofacial Research, Bethesda, 2National Cancer Institute, Bethesda, MD, 3National Cancer Institute, Bethesda, 4National Institute of Dental and Craniofacial Research, Bethesda, MD, 5National Institute of Allergy and Infectious Disease, Bethesda, MD, 6Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Immune checkpoint inhibitors (ICI) have advanced the field of cancer therapeutics. By blocking the negative co-stimulation of T cells, ICI augment the anti-tumor immune…
  • Abstract Number: 0843 • ACR Convergence 2020

    Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus

    Nick Huang1, Akshay Patel1, Zachary Oaks1 and Andras Perl1, 1SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: HRES-1/Rab4 or Rab4A, a GTPase responsible for mitochondrial oxidative stress1 and activation of the mechanistic target of rapamycin2, is overexpressed in T cells of…
  • Abstract Number: 1568 • ACR Convergence 2020

    Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study

    Nilasha Ghosh1, Aidan Tirpack2, Caroline Benson3, Gregory Vitone3, Karmela Kim Chan2 and Anne Bass1, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, New York

    Background/Purpose: It is not known whether cancer patients being treated with immune checkpoint inhibitors (ICI) and/or immunosuppression are more vulnerable to SARS-CoV-2 or more apt…
  • Abstract Number: 1996 • ACR Convergence 2020

    Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study

    Kevin Winthrop1, Juan Vargas2, Edit Drescher3, Conrado Garcia4, Alan Friedman5, Jeffrey Enejosa5, Nasser Khan5, Yihan Li5, Justin Klaff5 and Alan Kivitz6, 1Oregon Health & Science University, Portland, OR, 2Quantum Research, Puerto Varas, Chile, 3Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, 4Hospital General de México "Dr. Eduardo Liceaga", Mexico, Mexico, 5AbbVie Inc., North Chicago, IL, 6Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA

    Background/Purpose: Pneumococcal vaccination is recommended in patients with RA who are receiving conventional synthetic/biologic DMARDs.1 Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to…
  • Abstract Number: 0450 • ACR Convergence 2020

    In Vitro Characterization of Inflammatory Arthritis Associated with Immune Check Point Inhibition

    Anne Sofie Sørensen1, Morten Nørgaard Andersen1, Kristian Juul-Madsen2, Cæcilie Deisting Skejø1, Henrik Schmidt1, Thomas Vorup-Jensen1 and Tue Wenzel Kragstrup1, 1Aarhus University, Aarhus, Denmark, 2Aarhus University, Aarhus, Midtjylland, Denmark

    Background/Purpose: During treatment with immune checkpoint inhibitors (ICI) such as the anti-PD-1 antibody pembrolizumab, 2-4% of cancer patients develop inflammatory arthritis as an immune-related adverse…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology